# Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors

> **NCT05057130** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Blokhin's Russian Cancer Research Center** · enrollment: 50 (estimated)

## Conditions studied

- Osteosarcoma
- Neoplasms, Connective Tissue
- Neoplasms, Connective and Soft Tissue
- Sarcoma
- Sarcoma of Bone

## Interventions

- **DRUG:** Doxorubicin, Cisplatin, Methotrexate
- **DRUG:** Doxorubicin, Cisplatin

## Key facts

- **NCT ID:** NCT05057130
- **Lead sponsor:** Blokhin's Russian Cancer Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-10
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05057130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05057130, "Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05057130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*